Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Phase 2 Unknown 140 enrolled Adherex Technologies, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine if eniluracil/5-FU/leucovorin in metastatic breast cancer (MBC) may have efficacy and tolerability advantages over capecitabine monotherapy.

Timeline

Start: 2011-04
Primary completion: 2012-08
Completion: 2013-01

Publications

Hoon SN, Lau PK, White AM, Bulsara MK, Banks PD, Redfern AD. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer. Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Capecitabine	Small molecule	1000 mg/m2	Oral
Subject	Leucovorin	Small molecule	30 mg	Oral
Subject	eniluracil	Unknown	40 mg	Oral
Subject	fluorouracil	Small molecule	30 mg/m2	Oral

Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Summary

Timeline

Publications

Drugs

Indications